{
    "organizations": [],
    "uuid": "94eadcae7faed3b71f7c11b61f46e40f545abf18",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sage-therapeutics-says-sage-217-me/brief-sage-therapeutics-says-sage-217-met-primary-endpoint-of-improved-sleep-efficiency-in-phase-1-2-study-idUSFWN1PQ0SW",
    "ord_in_thread": 0,
    "title": "BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - Sage Therapeutics Inc:\n* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS\n* SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT OF IMPROVED SLEEP EFFICIENCY AND DEMONSTRATED IMPROVEMENTS IN MAINTAINING SLEEP COMPARED TO PLACEBO\n* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL TOLERATED AND ALL ADVERSE EVENTS WERE MILD\n* SAGE THERAPEUTICS INC - BASED ON THE POSITIVE RESULTS, SAGE EXPECTS TO INITIATE CLINICAL DEVELOPMENT OF SAGE-217 IN DISORDERS OF SLEEP IN 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-31T19:14:00.000+02:00",
    "crawled": "2018-02-01T15:24:21.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "sage",
        "therapeutic",
        "inc",
        "sage",
        "therapeutic",
        "announces",
        "positive",
        "result",
        "trial",
        "model",
        "insomnia",
        "demonstrating",
        "activity",
        "sleep",
        "parameter",
        "supporting",
        "development",
        "potential",
        "treatment",
        "sleep",
        "disorder",
        "sage",
        "therapeutic",
        "met",
        "primary",
        "endpoint",
        "improved",
        "sleep",
        "efficiency",
        "demonstrated",
        "improvement",
        "maintaining",
        "sleep",
        "compared",
        "placebo",
        "sage",
        "therapeutic",
        "inc",
        "generally",
        "well",
        "tolerated",
        "adverse",
        "event",
        "mild",
        "sage",
        "therapeutic",
        "inc",
        "based",
        "positive",
        "result",
        "sage",
        "expects",
        "initiate",
        "clinical",
        "development",
        "disorder",
        "sleep",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}